Retatrutide, a new dual agonist of the GLP-1 binding site and glucose-dependent secreted polypeptide (GIP) binding site , is demonstrating promising data in preliminary patient trials . Ongoing https://bookmarkdistrict.com/story21091198/retatrutide-emerging-studies-and-potential-medical-applications